A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs
DOI:
https://doi.org/10.65336/WJAMS.2025.21101Keywords:
delicacy lymphoma, Steroids, metabolism, corticosteroids, immune system, immunosuppressiveAbstract
Steroids are substances with the intention of be as expected fashioned within the body. They assist in the direction of be in charge of numerous of the unusual behavior our body exertion. They make conform: the approach the body uses carbohydrates, proteins and fats, the impervious system, the poise of salty and water in our bodies and soreness. Steroids are able in the direction of what’s more surviving completed in a laboratory as medications. They be capable of subsist worn in malignancy treatment: to assist obliterate malignancy cells and make other malignancy treatments further effectual, in the direction of prevent or extravagance an sensitive to response, as drugs, to perk up craving, to condense melanoma symptom, such as hurting cause by means of inflammation in the region of a cancer, to extravagance tenderness cause by melanoma healing Prednisone is a corticosteroid worn in the direction of extravagance numerous circumstances, together with lessening malignancy symptoms. Prednisone is capable in the direction of furthermore continue living geared up for the duration of a laboratory bearing in mind with the intention of medication proposed intended for formulate employ of contained by melanoma healing. Steroids be recurrently precise by proceeds of chemotherapy in the track of let somebody use a hand over treat lymphoma. They probably resolve to boot assist be alive conscious of improved all the way through chemotherapy. The steroids not quite all and sundry recurrently shabby in the path of delicacy lymphoma is called Prednisone. Steroids are substance messenger (hormone) that is through unsurprisingly within your body.
References
1. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010 Nov;11(11):1096-106. doi: 10.1016/S1470-2045(10)70114-5.
2. Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan
3. Paczula A, Wiecek A, Piecha G. Cardiotonic Steroids-A Possible Link Between High-Salt Diet and Organ Damage. Int J Mol Sci. 2019 Jan 30;20(3):590. doi: 10.3390/ijms20030590.
4. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018 Oct 1;32(19-20):1267-1284. doi: 10.1101/gad.314617.118.
5. Puckett Y, Gabbar A, Bokhari AA. Prednisone. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan
6. Bunte K, Smith DJ, Chappell MJ, Hassan-Smith ZK, Tomlinson JW, Arlt W, Tiňo P. Learning pharmacokinetic models for in vivo glucocorticoid activation. Journal of theoretical biology. 2018 Oct 14:455():222-231. doi: 10.1016/j.jtbi.2018.07.025.
7. Martinez FJ, Lederer DJ. Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment. Chest. 2018 Oct:154(4):978-979. doi: 10.1016/j.chest.2018.08.1021.
8. Puckett Y, Zhang K, Blasingame J, Lorenzana J, Parameswaran S, Brooks Md Facs SE, Baronia BC, Griswold J. Safest Time to Resume Oral Anticoagulation in Patients with Traumatic Brain Injury. Cureus. 2018 Jul 3:10(7):e2920. doi: 10.7759/cureus.2920.
9. Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clinical pharmacokinetics. 2012 Nov:51(11):711-41. doi: 10.1007/s40262-012-0007-8.
10. Ryu RJ, Easterling TR, Caritis SN, Venkataramanan R, Umans JG, Ahmed MS, Clark S, Kantrowitz-Gordon I, Hays K, Bennett B, Honaker MT, Thummel KE, Shen DD, Hebert MF. Prednisone Pharmacokinetics during Pregnancy and Lactation. Journal of clinical pharmacology. 2018 Sep:58(9):1223-1232. doi: 10.1002/jcph.1122.
11. Bunte K, Smith DJ, Chappell MJ, Hassan-Smith ZK, Tomlinson JW, Arlt W, Tiňo P. Learning pharmacokinetic models for in vivo glucocorticoid activation. J Theor Biol. 2018 Oct 14;455:222-231.
12. Martinez FJ, Lederer DJ. Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment. Chest. 2018 Oct;154(4):978-979.
13. Puckett Y, Zhang K, Blasingame J, Lorenzana J, Parameswaran S, Brooks Md Facs SE, Baronia BC, Griswold J. Safest Time to Resume Oral Anticoagulation in Patients with Traumatic Brain Injury. Cureus. 2018 Jul 03;10(7):e2920.
14. Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet. 2012 Nov;51(11):711-41.
15. Ryu RJ, Easterling TR, Caritis SN, Venkataramanan R, Umans JG, Ahmed MS, Clark S, Kantrowitz-Gordon I, Hays K, Bennett B, Honaker MT, Thummel KE, Shen DD, Hebert MF. Prednisone Pharmacokinetics during Pregnancy and Lactation. J Clin Pharmacol. 2018 Sep;58(9):1223-1232.
16. Janowitz T, Kleeman S, Vonderheide RH. Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. Oncologist. 2021
17. Sikkander, A. M. (2022). Duct cancer evaluation in situ–review. In Acta Biology Forum (pp. 01-04).
18. Sikkander, M., Vedhi, C., & Manisankar, P. (2012). Cyclic voltammetric determination of 1, 4-Dihydro pyridine drugs using MWCNTs modified glassy carbon electrode. Der Chem. Sin, 3, 413-420.
19. A. Mohamed Sikkander (2022). Intrathecal Chemotherapy for Blood Cancer Treatment. Acta Biology Forum.V01i01, 14-17. DOI: https://doi.org/10.5281/zenodo.7008901
20. Sikkander, M., & Nasri, N. S. (2013). Review on Inorganic Nano crystals unique benchmark of Nanotechnology. Moroccan Journal of Chemistry, 1(2), J-Chem.
21. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2025). Tungsten-based compounds: A new frontier in cancer diagnosis and therapy. Journal of Applied Organometallic Chemistry, 5, 149-167.
22. Sikkander, A. R. M. (2025). RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT. Biomedical Engineering: Applications, Basis and Communications, 37(01), 2430003.
23. Yadav,H,C., Revanuri,N., Sikkander,A.R.M, 2025. Organometallic Compounds phototoxicityagaint cancer cells. Biomedical Engineering Applications Basis and Communications, 2550020. http://dx.doi.org/10.4015/S1016237225500206
24. Sikkander, A. R. M., Meena, M., Yadav, H., Wahi, N., & Lakshmi, V. V. (2024). Appraisal of the impact of applying organometallic compounds in cancer therapy. Journal of Applied Organometallic Chemistry, 4, 145-166.
